The US Food and Drug Administration (FDA) has granted a priority review for Cephalon’s Nuvigil, a new treatment for excessive sleepiness associated with jet lag.
Nuvigil, which would be the first jet lag treatment approved by the FDA, is indicated to improve wakefulness in patients with treated obstructive sleep apnea, shift work sleep disorder and narcolepsy.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The new drug application filed by Cephalon is based on data from a Phase III pivotal study that evaluated the efficacy and safety of Nuvigil (50 or 150mg/day) in 427 healthy adults over three days during travel from the US to Europe.
The most common adverse events in controlled clinical trials were headache, nausea, dizziness and insomnia.
